GoodRx Holdings (GDRX) Accumulated Expenses (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Accumulated Expenses data on file, last reported at $83.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 7.93% year-over-year to $83.7 million; the trailing twelve-month figure through Mar 2026 stood at $83.7 million (up 7.93% YoY), and the FY2025 full-year result was $86.7 million, up 4.05% from the prior year.
• Accumulated Expenses slipped to $83.7 million in Q1 2026, from $86.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $143.4 million in Q3 2025 to a low of $33.8 million in Q1 2022.
• A 5-year average of $74.0 million and a median of $73.2 million in 2024 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 351.0% in 2022, while the deepest fall reached 6.33% in 2022.
• Tracing GDRX's Accumulated Expenses over 5 years: stood at $47.5 million in 2022, then jumped by 50.09% to $71.3 million in 2023, then advanced by 16.83% to $83.3 million in 2024, then gained by 4.05% to $86.7 million in 2025, then slipped by 3.44% to $83.7 million in 2026.
• Business Quant data shows GDRX's Accumulated Expenses at $83.7 million in Q1 2026, $86.7 million in Q4 2025, and $143.4 million in Q3 2025.